The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer
Authors:
Open Access
- 13 February 2017
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 13 (4) , 2477-2482
Abstract
The Luminal A subtype of breast cancer expresses the estrogen receptor (ER)-α and progesterone receptor (PR), but not the human epidermal growth factor receptor (HER)-2 oncogene. This subtype of breast cancer responds to endocrine therapy involving the use of selective estrogen receptor modulators and/or inhibitors of estrogen biosynthesis. However, these therapeutic agents are frequently associated with long-term systemic toxicity and acquired tumor resistance, emphasizing the need to identify non-toxic alternative treatments for chemo-endocrine therapy responsive breast cancer. The present study utilized the human mammary carcinoma-derived, ER+/PR+/HER-2− MCF-7 cell line as a model of the Luminal A subtype of breast cancer to examine the growth inhibitory effect of the Chinese nutritional herb Epimedium grandiflorum (EG) and determine the mechanisms underlying this effect. MCF-7 cells maintained in a serum-depleted culture medium retained their ability to grow in response to 17β-estradiol (E2). Treatment of the MCF-7 cells with EG resulted in dose-dependent inhibition of E2-promoted growth. Mechanistically, EG inhibited E2-promoted cell cycle progression through G1 stage arrest and modulated the cellular metabolism of E2, increasing the formation of the anti-proliferative metabolites 2-hydroxyestrone and estriol. Long-term treatment of MCF-7 cells with EG inhibited E2-promoted anchorage independent growth, a surrogate in vitro biomarker of tumorigenesis. In conclusion, the results of the present study demonstrate the growth inhibitory effects of EG on MCF-7 cells and identified clinically relevant mechanistic leads for its anti-tumorigenic efficacy.Keywords
This publication has 28 references indexed in Scilit:
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- The evolution of treatment strategies: Aiming at the targetThe Breast, 2007
- Estrogen Carcinogenesis in Breast CancerNew England Journal of Medicine, 2006
- New Estrogenic Prenylflavone fromEpimedium brevicornumInhibits the Growth of Breast Cancer CellsPlanta Medica, 2005
- Aromatase inhibitors for breast cancer: lessons from the laboratoryNature Reviews Cancer, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- The Role of Estrogen in Mammary CarcinogenesisaAnnals of the New York Academy of Sciences, 1995
- Alteratioon in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agentsSteroids, 1993
- Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?Breast Cancer Research and Treatment, 1983
- In Vitro Model Systems for the Study of Hormone-Dependent Human Breast CancerNew England Journal of Medicine, 1977